Triplet Therapeutics launches with $59 million to develop antisense therapies for Huntington's and more
Friday, January 3, 2020 - 17:10
in Health & Medicine
The start-up believes a single target could stall the development of dozens of triplet-repeat diseases, including Huntington's and myotonic dystrophy